---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-030260"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2021-12-02T23:59:59+00:00"
generated_at: "2026-06-28T04:15:30.816398+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics appoints Mark J. Gilbert to Board, replacing Hoonmo Lee

## Summary
- Hoonmo Lee resigned from the Board effective Nov. 29, 2021, with no disagreement.
- Board elected Mark J. Gilbert, M.D. as Class I director, term until 2022 annual meeting.
- Dr. Gilbert is EVP of R&D at Acepodia, former CMO of Juno Therapeutics.
- Dr. Gilbert granted option to purchase 20,000 shares at $5.35/share, vesting in 1 year.
- Eligible for annual retainer of $50,000 and additional option grants at each annual meeting.

## SEC filing metadata
- accession: 0001493152-21-030260
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2021-12-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-030260
- JSON: https://secwatch.observer/filing/0001493152-21-030260.json
- Plain text: https://secwatch.observer/filing/0001493152-21-030260.txt

## Key facts
- Executive change
  Hoonmo Lee resigned as Director at Indaptus Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), and from all committees of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm
- Executive change
  Mark J. Gilbert was elected as Director at Indaptus Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: On the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.